The feasibility and efficacy of intracranial stenting were evaluated for patients with a stroke-in-evolution after the time window for thrombolysis.
Patients with symptomatic intracranial steno-occlusive disease with progressive or fluctuating symptoms were treated using intracranial stenting after the time window for hyperacute thrombolysis.
Within the study period, we identified 10 patients (7 men, 62.5 ± 11.3 years old) who were eligible for inclusion. The median onset-to-arrival time was 5.8 hours (range: .6-144 hours), and the median onset-to-procedure time was 33 hours (range: 8-346 hours). Only 1 patient previously received intravenous thrombolysis using alteplase. The symptomatic occlusive artery was the right middle cerebral artery, left middle cerebral artery, and basilar artery in 3, 1, and 6 patients, respectively. The median initial National Institutes of Health Stroke Scale (NIHSS) score was 4 (range: 0-6), and the median NIHSS score measured immediately before the procedure was 8 (range: 4-26). All but 1 patient underwent successful angioplasty and stenting using a Wingspan stent. Reocclusion of the stented artery occurred in 1 patient, and his neurological status deteriorated to coma. A favorable outcome (modified Rankin Scale ≤2) at 3 months was noted in 7 patients (70%).
Intracranial stenting could be considered an alternative strategy for treating patients with medically intractable stroke-in-evolution.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Journal of Stroke and Cerebrovascular Diseases
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association.Stroke. 2013; 44: 2064-2089
- Atherosclerotic intracranial arterial stenosis: risk factors, diagnosis, and treatment.Lancet Neurol. 2013; 12: 1106-1114
- Natural history of intracranial atherosclerotic disease.Front Neurol. 2014; 5: 125
- Predictors of neurological deterioration during hospitalization: results from the Chinese Intracranial Atherosclerosis (CICAS) Study.Neurol Res. 2015; 37: 385-390
- Endovascular mechanical thrombectomy for acute ischemic stroke: a new standard of care.J Stroke. 2015; 17: 123-126
- Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association.Stroke. 2014; 45: 2160-2236
- Stenting versus aggressive medical therapy for intracranial arterial stenosis.N Engl J Med. 2011; 365: 993-1003
- Progression of stroke after arrival at hospital.Stroke. 1985; 16: 629-632
- Stroke-in-evolution: infarct-inherent mechanisms versus systemic causes.Cerebrovasc Dis. 2006; 21: 42-46
- Deteriorating stroke: diagnostic criteria, predictors, mechanisms and treatment.Cerebrovasc Dis. 1999; 9: 1-8
- Thrombolysis in patients with marked clinical fluctuations in neurologic status due to cerebral ischemia.Arch Neurol. 2008; 65: 1041-1043
- C-reactive protein is a predictor of early neurologic deterioration in acute ischemic stroke.J Stroke Cerebrovasc Dis. 2012; 21: 181-186
- Steno-occlusive arterial disease and early neurological deterioration in acute ischemic stroke.Cerebrovasc Dis. 2008; 25: 151-156
- MRI findings may predict early neurologic deterioration in acute minor stroke or transient ischemic attack due to intracranial atherosclerosis.Eur Neurol. 2010; 64: 95-100
- Internal and cortical border-zone infarction: clinical and diffusion-weighted imaging features.Stroke. 2006; 37: 841-846
- Mechanisms of acute cerebral infarctions in patients with middle cerebral artery stenosis: a diffusion-weighted imaging and microemboli monitoring study.Ann Neurol. 2002; 52: 74-81
- Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis.N Engl J Med. 2005; 352: 1305-1316
- Partial aortic occlusion for cerebral perfusion augmentation: safety and efficacy of NeuroFlo in Acute Ischemic Stroke trial.Stroke. 2011; 42: 1680-1690
- High-dose albumin treatment for acute ischaemic stroke (ALIAS) Part 2: a randomised, double-blind, phase 3, placebo-controlled trial.Lancet Neurol. 2013; 12: 1049-1058
- Effect of a balloon-expandable intracranial stent vs medical therapy on risk of stroke in patients with symptomatic intracranial stenosis: the VISSIT randomized clinical trial.JAMA. 2015; 313: 1240-1248
- First Food and Drug Administration-approved prospective trial of primary intracranial stenting for acute stroke: SARIS (stent-assisted recanalization in acute ischemic stroke).Stroke. 2009; 40: 3552-3556
Published online: March 22, 2016
Accepted: January 31, 2016
Received in revised form: January 10, 2016
Received: October 28, 2015
© 2016 National Stroke Association. Published by Elsevier Inc. All rights reserved.